Study to Obtain Blood and Tissue Samples from Subjects Being Treated
With Yervoy For the Treatment of Melanoma
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that it
has entered into a research study agreement with University of
Massachusetts Medical School (UMMS), which includes that institution’s
clinical partner, UMass Memorial Health Care, Inc. Pursuant to the study
agreement, UMass Medical School will provide Enumeral with tissue
samples and blood samples from subjects with melanoma who are being
treated with Ipilimumab (Yervoy). Enumeral will fund the tissue
collection activities, and Enumeral will have access to the samples for
research-only use in in-vitro studies.
“We are very excited to partner with the University of Massachusetts
Medical School and UMass Memorial Health Care in this research study.
Information our platform generates in such longitudinal studies could
enable us to generate insights into which immunotherapeutic strategies
may be successful in patients that are not well-treated by currently
marketed drugs,” said Arthur H. Tinkelenberg, Ph.D., Enumeral’s
President and Chief Executive Officer.
“This collaboration will allow us to study the effects of checkpoint
blockade on the immune system at single cell resolution, by analyzing
blood and tumor-tissue directly from individual patients using
Enumeral’s unique immunoprofiling platform. This is the basis of our
translational strategy to support development of novel
immunotherapeutics --- what we call our Human Approach,” added M. Isabel
Chiu, Ph.D., Enumeral’s Vice President of Translational and Clinical
Sciences.
Enumeral’s scientists will apply the company’s proprietary platform
technology to analyze single immune cells within the patient samples.
The study will be conducted under the direction of William Walsh, M.D.,
Clinical Associate Professor of Medicine at UMMS and principal
investigator.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents,
Enumeral’s researchers apply a proprietary immune profiling technology
platform that measures functioning of the human immune system at the
level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School, one of the fastest
growing academic health centers in the country, has built a reputation
as a world-class research institution, consistently producing noteworthy
advances in clinical and basic research. UMMS attracts more than $240
million in research funding annually, 80 percent of which comes from
federal funding sources. The mission of the medical school is to advance
the health and well-being of the people of the commonwealth and the
world through pioneering education, research, public service and health
care delivery with its clinical partner, UMass Memorial Health Care. For
more information, visit www.umassmed.edu.
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Such statements reflect current beliefs of Enumeral Biomedical
Holdings, Inc. (“Enumeral”) with respect to future events and involve
known and unknown risks, uncertainties, and other factors affecting
operations, market growth, Enumeral’s stock price, services, products
and licenses. No assurances can be given regarding the achievement of
future results, and although Enumeral believes that the expectations
reflected in these forward-looking statements are based on reasonable
assumptions, actual results may differ from the assumptions underlying
the statements that have been made regarding anticipated events. Factors
that may cause actual results, performance or achievements, or industry
results to differ materially from those contemplated by such
forward-looking statements include, among others, the risks that (a)
Enumeral’s expectations regarding market acceptance of the Company’s
business in general and the Company’s ability to penetrate the antibody
discovery and development fields in particular, as well as the timing of
such acceptance, (b) Enumeral’s ability to attract and retain management
with experience in biotechnology and antibody discovery and similar
emerging technologies, (c) the scope, validity and enforceability of
Enumeral’s and third party intellectual property rights, (d) Enumeral’s
ability to raise capital when needed and on acceptable terms and
conditions, (e) Enumeral’s ability to comply with governmental
regulation, (f) the intensity of competition, (g) changes in the
political and regulatory environment and in business and fiscal
conditions in the United States and overseas and (h) general economic
conditions.
More detailed information about Enumeral and risk factors that may
affect the realization of forward-looking statements, including
forward-looking statements in this press release, is set forth in
Enumeral’s filings with the Securities and Exchange Commission. Enumeral
urges investors and security holders to read those documents free of
charge at the Commission’s website at http://www.sec.gov.
Forward-looking statements speak only as to the date they are made, and
except for any obligation under the U.S. federal securities laws,
Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150826005515/en/
Copyright Business Wire 2015